|

Imetelstat Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: GRN 163L, GRN-163L, GRN163L

Pipeline

Phase 1: 2

Top Sponsors

  • Douglas Tremblay1
  • Children's Oncology Group1

Indications

  • Cancer2
  • Refractory Juvenile Myelomonocytic Leukemia1
  • Refractory Childhood Myelodysplastic Syndrome1
  • Refractory Childhood Acute Myeloid Leukemia1
  • Recurrent Juvenile Myelomonocytic Leukemia1

Birmingham, Alabama1 trial

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Hospital of Alabama

Phase 1

New York, New York1 trial

Imetelstat Combinations in Relapsed AML

Icahn School of Medicine at Mount Sinai

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.